The results indicate that treatment with SM-3 reduced the activation of mTOR and Akt in lung cancer cells, as evidenced by lower levels of both phosphorylated and total protein expressions compared to the parent compound, Res (Fig. 7). The gene discussed is MTOR; the disease is lung carcinoma.